. "4" . "Bevacizumab: current status of malignant tumors treatment"@en . . . . "Proces angiogeneze je z\u00E1sadn\u00ED v r\u016Fstu a metastazov\u00E1n\u00ED malign\u00EDch n\u00E1dor\u016F a mo\u017Enosti jeho ovlivn\u011Bn\u00ED jsou ji\u017E n\u011Bkolik let v pop\u0159ed\u00ED z\u00E1jmu v onkologii. V sou\u010Dasnosti jsou ji\u017E v klinick\u00E9 praxi dostupn\u00E1 l\u00E9\u010Diva c\u00EDlen\u00E1 na proces angiogeneze, kter\u00E1 prok\u00E1zala sv\u016Fj p\u0159\u00EDnos v \u0159ad\u011B klinick\u00FDch studi\u00ED, i kdy\u017E v\u00FDzkum p\u0159in\u00E1\u0161\u00ED st\u00E1le nov\u00E9 detailn\u00ED poznatky. Humanizovan\u00E1 monoklon\u00E1ln\u00ED protil\u00E1tka proti VEGF bevacizumab je v l\u00E9\u010Db\u011B solidn\u00EDch n\u00E1dor\u016F z t\u011Bchto l\u00E9k\u016F zat\u00EDm nej\u00FAsp\u011B\u0161n\u011Bj\u0161\u00ED a ji\u017E pat\u0159\u00ED do standardn\u00ED l\u00E9\u010Dby metastatick\u00E9ho karcinomu kolorekta a nach\u00E1z\u00ED uplatn\u011Bn\u00ED v l\u00E9\u010Db\u011B karcinomu prsu, ledvin a plic. Prob\u00EDhaj\u00ED \u010Detn\u00E9 studie zkoumaj\u00EDc\u00ED uplatn\u011Bn\u00ED bevacizumabu u jin\u00FDch solidn\u00EDch malignit. Ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky jsou dob\u0159e zn\u00E1my a jejich profil je pom\u011Brn\u011B p\u0159\u00EDzniv\u00FD. \u010Cl\u00E1nek p\u0159in\u00E1\u0161\u00ED z\u00E1kladn\u00ED p\u0159ehled o postaven\u00ED bevacizumabu v l\u00E9\u010Db\u011B zm\u00EDn\u011Bn\u00FDch malignit a v\u00FDsledk\u016F klinick\u00FDch studi\u00ED." . "CZ - \u010Cesk\u00E1 republika" . "Bevacizumab: sou\u010Dasn\u00E9 postaven\u00ED v l\u00E9\u010Db\u011B solidn\u00EDch n\u00E1dor\u016F" . . . "I" . . "Proces angiogeneze je z\u00E1sadn\u00ED v r\u016Fstu a metastazov\u00E1n\u00ED malign\u00EDch n\u00E1dor\u016F a mo\u017Enosti jeho ovlivn\u011Bn\u00ED jsou ji\u017E n\u011Bkolik let v pop\u0159ed\u00ED z\u00E1jmu v onkologii. V sou\u010Dasnosti jsou ji\u017E v klinick\u00E9 praxi dostupn\u00E1 l\u00E9\u010Diva c\u00EDlen\u00E1 na proces angiogeneze, kter\u00E1 prok\u00E1zala sv\u016Fj p\u0159\u00EDnos v \u0159ad\u011B klinick\u00FDch studi\u00ED, i kdy\u017E v\u00FDzkum p\u0159in\u00E1\u0161\u00ED st\u00E1le nov\u00E9 detailn\u00ED poznatky. Humanizovan\u00E1 monoklon\u00E1ln\u00ED protil\u00E1tka proti VEGF bevacizumab je v l\u00E9\u010Db\u011B solidn\u00EDch n\u00E1dor\u016F z t\u011Bchto l\u00E9k\u016F zat\u00EDm nej\u00FAsp\u011B\u0161n\u011Bj\u0161\u00ED a ji\u017E pat\u0159\u00ED do standardn\u00ED l\u00E9\u010Dby metastatick\u00E9ho karcinomu kolorekta a nach\u00E1z\u00ED uplatn\u011Bn\u00ED v l\u00E9\u010Db\u011B karcinomu prsu, ledvin a plic. Prob\u00EDhaj\u00ED \u010Detn\u00E9 studie zkoumaj\u00EDc\u00ED uplatn\u011Bn\u00ED bevacizumabu u jin\u00FDch solidn\u00EDch malignit. Ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky jsou dob\u0159e zn\u00E1my a jejich profil je pom\u011Brn\u011B p\u0159\u00EDzniv\u00FD. \u010Cl\u00E1nek p\u0159in\u00E1\u0161\u00ED z\u00E1kladn\u00ED p\u0159ehled o postaven\u00ED bevacizumabu v l\u00E9\u010Db\u011B zm\u00EDn\u011Bn\u00FDch malignit a v\u00FDsledk\u016F klinick\u00FDch studi\u00ED."@cs . "[627A15C29633]" . "Bevacizumab: current status of malignant tumors treatment"@en . . "Bevacizumab: sou\u010Dasn\u00E9 postaven\u00ED v l\u00E9\u010Db\u011B solidn\u00EDch n\u00E1dor\u016F"@cs . "Bevacizumab: sou\u010Dasn\u00E9 postaven\u00ED v l\u00E9\u010Db\u011B solidn\u00EDch n\u00E1dor\u016F" . "Bevacizumab: sou\u010Dasn\u00E9 postaven\u00ED v l\u00E9\u010Db\u011B solidn\u00EDch n\u00E1dor\u016F"@cs . "Tom\u00E1\u0161ek, Ji\u0159\u00ED" . "RIV/00216224:14110/10:00051746!RIV12-MSM-14110___" . "Angiogenesis is a key process in growth and metastatic spread of malignant tumors. Enthusiastic research over past years has produced several therapeutic agents targeting angiogenesis, available in clinical practice. The most advanced in the treatment of solid tumors at present time is bevacizumab, a humanized monoclonal anti-VEGF antibody. It has become a part of standard treatment of metastatic colorectal cancer and is settling in the treatment of breast, kidney and lung cancers. To determine the role of bevacizumab in the treatment of other solid malignancies, there are many clinical trials ongoing. The toxicity profile has been well described and is quite favorable. The article brings a basic overview of the clinical use of bevacizumab based on clinical studies."@en . . . "4"^^ . "angiogenesis; bevacizumab; VEGF; solid tumors"@en . . . . "2"^^ . "248661" . "Tu\u010Dek, \u0160t\u011Bp\u00E1n" . . "RIV/00216224:14110/10:00051746" . . "2"^^ . "Onkologie" . "14110" . "3" . . "1802-4475" .